Domka K, Dąbkowska A, Janowska M, Urbańska Z, Pastorczak A, Winiarska M, Fidyt K, Lachota M, Patkowska E, Sędek Łukasz, Perkowski B, Hunia J, Jakubowska J, Krzymieniewska B, Lech-Marańda E, Młynarski W, Szczepański T, Firczuk M. Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20<sup>+</sup&gt; Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models. Haematologica 2024;109(11):3520-3532; https://doi.org/10.3324/haematol.2023.284853.